Before designing anything, read the last three access decisions word for word: the letter itself, not the internal summary. The question raised is usually specific, and much narrower than the program being scoped to answer it.
What tends to come up
- Durability beyond twelve months, where the pivotal trial stopped at twelve.
- Adherence in a real-world population rather than a trial one.
- Total cost of care including the setting of administration.
- Comparative outcomes in a subgroup the trial under-enrolled.
A rigorous study answering a different question makes a good publication. Matching the question makes it an access lever as well, and the incremental cost of aligning the two at design time is usually small.
Design choices that decide how it lands
| Look for | Be wary of |
|---|---|
| The comparator the payer already uses | A comparator chosen for a favorable contrast |
| Endpoint and analysis plan pre-specified, and stated | Post-hoc findings introduced during negotiation |
| The population you could not observe, described plainly | A clean result with an unexplained denominator |
| Total cost of care, including administration setting | Drug cost considered in isolation |
Where the calendar actually goes
Analysis is the short part. Establishing which claims, EHR and registry assets can be linked lawfully, then agreeing terms, is where the months sit. Running that procurement alongside protocol design rather than after it is the largest schedule saving available in most programs.
The strongest evidence packages usually state their own weakest link up front.
Sources and further reading
- Real-World Evidence program, U.S. Food and Drug Administration. Retrieved: to be re-verified.
- News and guidance, National Institute for Health and Care Excellence. Retrieved: to be re-verified.